NCT03647982已完成1 期
Open-Label, Active Controlled, Single-Center, Phase 1 Study to Determine the Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Volunteers
Medy-Tox1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2018年3月20日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- anhidrotic area
研究概览
简要总结
To determine the anhidrotic area and safety of MEDITOXIN
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male adults aged between 20 and 45 years
排除标准
- •Subjects not appropriate for participating in this study according to the investigator's opinion
研究组 & 干预措施
botulinum toxin 1U
Experimental
干预措施: Meditoxin (Drug)
botulinum toxin 1U
Experimental
干预措施: Botox (Drug)
botulinum toxin 3U(25U/1ml)
Experimental
干预措施: Meditoxin (Drug)
botulinum toxin 3U(25U/1ml)
Experimental
干预措施: Botox (Drug)
botulinum toxin 5U
Experimental
干预措施: Meditoxin (Drug)
botulinum toxin 5U
Experimental
干预措施: Botox (Drug)
botulinum toxin 10U
Experimental
干预措施: Meditoxin (Drug)
botulinum toxin 10U
Experimental
干预措施: Botox (Drug)
botulinum toxin 3U(50U/1ml)
Experimental
干预措施: Meditoxin (Drug)
botulinum toxin 3U(50U/1ml)
Experimental
干预措施: Botox (Drug)
botulinum toxin 3U(12.5U/1ml)
Experimental
干预措施: Meditoxin (Drug)
botulinum toxin 3U(12.5U/1ml)
Experimental
干预措施: Botox (Drug)
结局指标
主要结局
anhidrotic area
时间窗: week 4
After the ninhydrin sweat test, measure the area of the unstained area
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
CMOEP in the Treatment of Untreated Peripheral T-cell LymphomaPeripheral T-cell LymphomaNCT05458180Tianjin Medical University Cancer Institute and Hospital18
招募中
1 期
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCLTreatmentPeripheral T-cell LymphomaNCT05441761Peking Union Medical College Hospital60
终止
1 期
Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous DocetaxelMedical OncologyNCT02439346Bayer15
Unknown
1 期
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid TumorsMedulloblastomaAdenocarcinoma of Esophagogastric JunctionSmall Cell Lung CancerNeuroendocrine NeoplasmBasal Cell CarcinomaGlioblastomaNCT03734913Guangdong Zhongsheng Pharmaceutical Co., Ltd.65
Unknown
1 期
A Phase 1 Study of ZSP1241 in Participants With Advanced Solid TumorsColorectal CancerHepatocellular CarcinomaGastric CancerEsophageal CancerCholangiocarcinomaNCT03734926Guangdong Zhongsheng Pharmaceutical Co., Ltd.90